Medy-Tox Tests New Botulinum Toxin Formulation MBA-P01 for Glabellar Lines
A Phase 2 trial evaluates MBA-P01, a novel botulinum toxin A, for safety and optimal dosing in treating frown lines.
22 articles in this topic
A Phase 2 trial evaluates MBA-P01, a novel botulinum toxin A, for safety and optimal dosing in treating frown lines.
A Phase 1/2 trial tests four rounds of intrathecal MSC injections in ALS patients, targeting both safety and disease progression.
A terminated multicenter RCT examined whether mechanical cough assistance plus NIV could cut re-intubation rates in ICU patients with weak cough.
Small trial tests autologous bronchial stem cells to repair damaged lung tissue in chronic obstructive pulmonary disease patients.
Adipose-derived stem cells combined with platelet-rich plasma evaluated for treating moderate to severe knee osteoarthritis over 2 years.
Small trial tests blood-derived therapy for persistent post-surgical ear infections that resist standard treatments.
Autologous stem cell injections tested in patients with severe leg circulation problems who had no surgical options.
Researchers compared stem cells from arthritis patients versus healthy donors to assess regenerative therapy potential.
32-person trial compared bone marrow stem cells, platelet therapy, and hyaluronic acid for knee arthritis treatment over one year.
Small pilot study tests whether enriched fat transfers can reduce amputation site pain and improve prosthetic use.
Study shows intensive glucose management increases cardiac stem cells in heart attack patients, potentially improving recovery.
Small pilot study explores whether PRP injections can safely reverse aging signs in women's facial and hand skin.